Argen X SE - ADR

NASDAQ:ARGX 4:00:00 PM EDT

401.96

+0.90 (+0.22%)

4:33:55 PM EDT: $401.96 0.00 (0.00%)

Market Cap (Intraday)	22.43B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$242.59 Million
Adjusted EPS	-$1.93

See more estimates

10-Day MA	$406.09
50-Day MA	$387.61
200-Day MA	$376.83

See more pivots

Argen X SE - ADR Stock, NASDAQ:ARGX

Willemstraat 5, Breda, Noord-Brabant 4811 AH

Netherlands

Phone: +31.76.303.04.88

Number of Employees: 843

http://www.argenx.com

Description

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.